share_log

AbbVie | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

AbbVie | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

艾伯维公司 | S-8：员工福利计划证券登记
美股SEC公告 ·  11/04 13:21

Moomoo AI 已提取核心信息

AbbVie Inc., a biopharmaceutical company incorporated in Delaware, has filed a Registration Statement on Form S-8 with the United States Securities and Exchange Commission (SEC) on November 4, 2024. The purpose of this filing is to register additional shares of common stock that may be offered or sold under the AbbVie Savings Program. This program is designed for employee participation and the registration also covers an indeterminate amount of plan interests. The filing is in accordance with General Instruction E to Form S-8, which pertains to the registration of additional securities. AbbVie Inc. has referenced its prior Registration Statement from December 19, 2012, and has included exhibits detailing its corporate governance documents and the consent of Ernst & Young LLP. The company has confirmed compliance with IRS regulations for the AbbVie Savings Program to qualify under Section 401 of the U.S. Internal Revenue Code. The Registration Statement has been signed by key executives including the CEO, CFO, and other directors of AbbVie Inc.
AbbVie Inc., a biopharmaceutical company incorporated in Delaware, has filed a Registration Statement on Form S-8 with the United States Securities and Exchange Commission (SEC) on November 4, 2024. The purpose of this filing is to register additional shares of common stock that may be offered or sold under the AbbVie Savings Program. This program is designed for employee participation and the registration also covers an indeterminate amount of plan interests. The filing is in accordance with General Instruction E to Form S-8, which pertains to the registration of additional securities. AbbVie Inc. has referenced its prior Registration Statement from December 19, 2012, and has included exhibits detailing its corporate governance documents and the consent of Ernst & Young LLP. The company has confirmed compliance with IRS regulations for the AbbVie Savings Program to qualify under Section 401 of the U.S. Internal Revenue Code. The Registration Statement has been signed by key executives including the CEO, CFO, and other directors of AbbVie Inc.
艾伯维公司是一家总部位于特拉华州的生物制药公司，于2024年11月4日向美国证券交易委员会（SEC）提交了Form S-8的注册声明。此次申报的目的是注册额外的普通股股份，这些股份可能在艾伯维储蓄计划下进行发行或出售。该计划旨在供员工参与，注册也涵盖了不确定数量的计划权益。该申报符合Form S-8的E通用说明，涉及额外证券的注册。艾伯维公司参考了其2012年12月19日的先前注册声明，并包括详细展示公司治理文件及安氏会计事务所的同意书。公司已确认符合美国《内部收入法典》第401条的艾伯维储蓄计划的IRS法规要求。注册声明已由首席执行官、首席财务官和艾伯维公司的其他董事签署。
艾伯维公司是一家总部位于特拉华州的生物制药公司，于2024年11月4日向美国证券交易委员会（SEC）提交了Form S-8的注册声明。此次申报的目的是注册额外的普通股股份，这些股份可能在艾伯维储蓄计划下进行发行或出售。该计划旨在供员工参与，注册也涵盖了不确定数量的计划权益。该申报符合Form S-8的E通用说明，涉及额外证券的注册。艾伯维公司参考了其2012年12月19日的先前注册声明，并包括详细展示公司治理文件及安氏会计事务所的同意书。公司已确认符合美国《内部收入法典》第401条的艾伯维储蓄计划的IRS法规要求。注册声明已由首席执行官、首席财务官和艾伯维公司的其他董事签署。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    MIRA Pharmaceuticals
    MIRA
    -- 1.060
    Medicus Pharma
    MDCX
    -- 2.580
    艾伯维公司
    ABBV
    -- 175.580
    辉瑞
    PFE
    -- 26.360
    施贵宝
    BMY
    -- 57.330

    解锁榜首股票